Altre lingue IRLAB Therapeutics AB

Azioni

IRLAB A

SE0012675361

Mercato chiuso - Nasdaq Stockholm Altri mercati azionari 17:29:43 31/05/2024			Variaz. 5gg	Var. 1 gen.
15,6 ^SEK	-0,95%		-0,95%	+108,00%

27/05	La svedese IRLAB Therapeutics nomina un nuovo amministratore delegato	MT
27/05	IRLAB Therapeutics AB (publ) annuncia un cambio di CEO, con effetto dal 1° agosto 2024	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Sweden’s IRLAB Therapeutics Names New CEO	27/05
IRLAB Therapeutics AB Announces CEO Changes, Effective from August 1, 2024	27/05
IRLAB Therapeutics AB Administers the First Dose in A Phase I Clinical Trial with the Drug Candidate Irl757	22/05
Transcript : IRLAB Therapeutics AB, Q1 2024 Earnings Call, May 08, 2024	08/05
IRLAB Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
IRLAB Therapeutics AB and McQuade Center for Strategic Research and Development, LLC Enter into Development Collaboration for IRL757 as Novel Treatment for Apathy	07/05
IRLAB Has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757	06/05
IRLAB Therapeutics Receives Minutes from End-of-Phase 2 Meeting Confirming Alignment with the FDA on the Phase III Program for Mesdopetam	22/03
IRLAB Therapeutics AB Mesdopetam Displays Antipsychotic Properties in an Advanced Model of Parkinson's Disease Psychosis	19/03
IRLAB Therapeutics AB Completes End-Of-Phase 2 Meeting with the FDA on the Design of the Phase III Program for Mesdopetam	22/02
Transcript : IRLAB Therapeutics AB, 2023 Earnings Call, Feb 07, 2024	07/02
IRLAB Therapeutics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	07/02
IRLAB's Pioneering Phase IIb Study Withpirepemat - React-PD - Provides New Insights in Specific Parkinson's Patient Population and Enables a Data Driven Prediction of Study Timelines	06/02
Irlab Therapeutics to Meet with US FDA for Mesdopetam Progam in February	03/01
IRLAB Is Granted an End-Of-Phase 2 Meeting with the FDA for the Phase III-Ready Mesdopetam Program	03/01
IRLAB Therapeutics AB Receives Grant from the Michael J. Fox Foundation to Support Development of IRL 757 for the Treatment of Apathy	21/12
IRLAB Therapeutics AB's Drug Candidate IRL757 Completes all Preclinical Studies and Development Work Necessary to Start Phase I	21/12
IRLAB Therapeutics AB Submits Request for an End-Of-Phase 2 Meeting with the FDA for the Phase III-Ready Mesdopetam Program	18/12
Irlab Therapeutics Secures European Patent for Parkinson’s Disease Drug Candidate	12/12
IRLAB Therapeutics AB Receives Additional Patent for Drug Candidate Pirepemat That Expands its Patent Protection	12/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue IRLAB Therapeutics AB

Azioni

IRLAB A

SE0012675361

Altre lingue

Filtri